Oryzon Genomics receives Decision to Grant from Japanese Patent Office

Oryzon Genomics (ORYZF) has received a “Decision to grant” communication from the Japanese Patent Office for its patent application JP2023-136283, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders. The allowed claims cover the use of vafidemstat for the treatment of aggression and social withdrawal – two symptoms associated with several CNS disorders. Oryzon is preparing a Phase III trial to evaluate vafidemstat for the treatment of aggression in borderline personality disorder. The Company is also preparing a Phase II trial in aggression in autism spectrum disorder patients, and a Phase II trial is already ongoing in schizophrenia. A “Decision to grant” is an official communication from a national patent office indicating that a patent application has met all requirements for issuance as a granted patent. Once formally granted, this Japanese patent will remain in force until at least 2038, excluding any potential patent term extension, which could provide additional years of protection. Corresponding patents have already been granted or allowed in Europe, Australia, Canada, Hong Kong, Israel, South Korea, Malaysia, the Philippines, and Russia, and additional applications are pending in other countries.